Sporanox Dosage/Direction for Use

For optimal absorption, administer SPORANOX capsules immediately after a full meal.
The capsules must be swallowed whole. (See Table 1, Table 2 and Table 3.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Elimination of itraconazole from skin and nail tissue is slower than from plasma. Optimal clinical and mycological response is thus reached 2 to 4 weeks after the cessation of treatment for skin infections and 6 to 9 months after the cessation of treatment for nail infections. (See Table 4.)

Click on icon to see table/diagram/image

Special Populations: Pediatrics: Clinical data on the use of SPORANOX capsules in pediatric patients are limited. The use of SPORANOX capsules in pediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks. (See Precautions.)
Elderly: Clinical data on the use of SPORANOX in elderly patients are limited. It is advised to use SPORANOX in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See Precautions.)
Hepatic impairment: Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See Pharmacology: Pharmacokinetics: Special Populations: Hepatic impairment under Actions).
Renal impairment: Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency. Caution should be exercised when this drug is administered in this patient population and adjusting the dose may be considered.